Actym to Present at the STING & TLR-Targeting Therapies Digital Summit, May 26, 2021

BERKELEY, CA – May 25, 2021

Actym Therapeutics announced that Dr. Laura Hix Glickman, Cofounder and Vice President of Research, has been invited to speak at the STING & TLR-Targeting Therapies Digital Summit on May 26, 2021. Dr. Glickman’s presentation, “STACT: A Novel Therapeutic Platform That Delivers Combination STING Immunotherapy to Tumor-Resident Myeloid Cells After IV Dosing” will begin at 9:25 AM, PST. Dr. Glickman will also participate in a panel discussion directly following the presentation.

About Actym

Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer. The company has developed an attenuated, microbial-based, immunotherapeutic technology platform called STACT (S. Typhimurium-Attenuated Cancer Therapy). In preclinical studies, STACT specifically enriches in many types of solid tumors and not in healthy tissue. Once there, STACT delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. Many of these payload targets are of significant interest to the biopharmaceutical community but are intractable using conventional approaches due to systemic toxicities after intravenous dosing. Furthermore, STACT has been engineered to deliver payload combinations, which facilitates engagement of multiple biological pathways from a single therapy. In April of 2020, Actym raised $34 million in a Series A financing, co-led by Boehringer-Ingelheim Venture Fund and Panacea Venture Healthcare, with participation from Illumina Ventures, Korea Investment Partners, and JLO Ventures.

​Media Contact:

Valerie Enes Seismic Media Relations valerie@teamseismic.com

Corporate Contact:

Sheriese Rush, MBA Head of Operations, Actym Therapeutics, Inc. srush@actymthera.com